Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Director departure

Ambrx Biopharma Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/12/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/12/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/12/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/12/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
10/12/2023 8-K Quarterly results
10/10/2023 8-K Quarterly results
10/10/2023 SC 13G HOPU Reunion Co Ltd reports a 8.9% stake in Ambrx Biopharma Inc.
10/06/2023 8-K Resignation/termination of a director
08/25/2023 8-K Other Events  Interactive Data
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/07/2023 4 O'Connor Daniel J. (President and CEO) has filed a Form 4 on Ambrx Biopharma Inc.
Txns: Granted 1,216,500 options to buy @ $0
07/07/2023 4 Nelson Sonja (CFO) has filed a Form 4 on Ambrx Biopharma Inc.
Txns: Granted 389,000 options to buy @ $0
07/07/2023 4 Aromando Andrew (COO) has filed a Form 4 on Ambrx Biopharma Inc.
Txns: Granted 389,000 options to buy @ $0
06/28/2023 4 Darwin Global Management, Ltd. (10% Owner) has filed a Form 4 on Ambrx Biopharma Inc.
Txns: Bought 5,384,063 options to buy @ $0
06/28/2023 SC 13D/A Darwin Global Management, Ltd. reports a 27.5% stake in Ambrx Biopharma Inc.
06/28/2023 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Ambrx Announces Closing of $75 Million Market Priced Registered Offering SAN DIEGO"
06/09/2023 4 Glover Stephen C. (Director) has filed a Form 4 on Ambrx Biopharma Inc.
Txns: Granted 85,000 shares @ $0
Granted 40,000 options to buy @ $0
Granted 17,500 options to buy @ $0
06/09/2023 4 Chang Xiaowei (Director) has filed a Form 4 on Ambrx Biopharma Inc.
Txns: Granted 85,000 options to buy @ $0
Granted 125,000 options to buy @ $0
06/09/2023 4 Loesberg Janet (Director) has filed a Form 4 on Ambrx Biopharma Inc.
Txns: Granted 85,000 shares @ $0
06/09/2023 4 MAIER PAUL V (Director) has filed a Form 4 on Ambrx Biopharma Inc.
Txns: Granted 85,000 shares @ $0
06/09/2023 4 Hermans Kate (Director) has filed a Form 4 on Ambrx Biopharma Inc.
Txns: Granted 85,000 shares @ $0
06/08/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/26/2023 4 Glover Stephen C. (Director) has filed a Form 4 on Ambrx Biopharma Inc.
Txns: Granted 210,000 options to buy @ $0
05/25/2023 SC 13D/A Darwin Global Management, Ltd. reports a 20.5% stake in Ambrx Biopharma Inc.
05/25/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Opinion of Maples & Calder (Hong Kong) LLP",
"Securities Purchase Agreement, by and between Ambrx Biopharma Inc. and the Purchasers",
"Ambrx Announces $75 Million Market Priced Registered Offering"
05/25/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/19/2023 3 Glover Stephen C. (Director) has filed a Form 3 on Ambrx Biopharma Inc.
05/18/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/18/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Ambrx Appoints Stephen Glover as Chairman of its Board of Directors"
05/16/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment to Executive Employment Agreement by and between the Company and Daniel J. O’Connor",
"Amendment to Executive Employment Agreement by and between the Company and Daniel J. O’Connor"
05/16/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/05/2023 4 Aromando Andrew (COO) has filed a Form 4 on Ambrx Biopharma Inc.
Txns: Granted 2,600,000 options to buy @ $0
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy